logo
logo
NRC stock ticker logo

National Research Corporation

NASDAQ•NRC
CEO: Mr. Michael D. Hays
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2013-05-23
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
連絡先情報
1245 Q Street, Lincoln, NE, 68508, United States
402-475-2525
www.nrchealth.com
時価総額
$423.46M
PER (TTM)
45.3
29.2
配当利回り
3.0%
52週高値
$22.79
52週安値
$11.01
52週レンジ
66%
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$34.80M+0.00%
直近4四半期の推移

EPS

$0.15+0.00%
直近4四半期の推移

フリーCF

$5.35M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Leading Indicator TRCV Growth Total Recurring Contract Value reached $144.1M in 2025, increasing 8% over 2024, signaling future revenue potential.
Operating Margin Compression Operating margin fell to 16% in 2025, down 9 points, driven by $6.6M in executive transition bonuses and lower revenue.
Strategic Nobl Acquisition Acquired Nobl Health in Q3 2024 for $6.3M consideration to expand rounding solutions and customer feedback portfolio.
New Credit Facility Secured Secured $110.0M Delayed Draw Term Loan in February 2025, ensuring liquidity for growth and future business acquisitions.

リスク要因

Revenue Concentration Risk Heavy reliance on contract renewals; top ten customers accounted for 20% of 2025 revenue, impacting operating results.
Intense Market Competition Highly competitive industry faces pricing pressure and increased marketing expenditures against larger rivals like Qualtrics.
Healthcare Regulation Impact Revenue tied to healthcare industry conditions; regulatory changes affecting Medicare/Medicaid could reduce customer demand.
Cybersecurity and Data Risk Exposure to cyber-attacks, ransomware, and data breaches impacting operations, liability, and reputational standing.

見通し

2026 Growth Expectation Expect revenue, operating margin, and cash flow growth in 2026 due to growing TRCV and lower expense run rate.
Growth Strategy Focus Strategy centers on cross-selling existing solutions, winning new customers, and developing new AI-enabled technologies.
New Leadership Alignment New senior management team appointed across CEO, COO, and CFO roles to execute evolving healthcare experience strategy.
Continued Technology Investment Plan to invest in R&D, including AI, to enhance solutions, though new offerings carry inherent development risks.

同業比較

売上高 (TTM)

TBRG stock ticker logoTBRG
$345.90M
-0.5%
HCAT stock ticker logoHCAT
$302.48M
-2.8%
VMD stock ticker logoVMD
$286.57M
+23.1%

粗利益率 (最新四半期)

PBYI stock ticker logoPBYI
76.7%
+13.8pp
SPOK stock ticker logoSPOK
73.8%
+19.3pp
SOPH stock ticker logoSOPH
68.0%
-0.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
NRC$423.46M45.357.2%58.0%
VMD$400.62M27.010.7%6.3%
TBRG$391.78M86.42.5%41.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.7%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年7月27日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし